Harvard Bioscience price target lowered to $4.50 from $5.50 at Benchmark

Benchmark lowered the firm’s price target on Harvard Bioscience (HBIO) to $4.50 from $5.50 and keeps a Speculative Buy rating on the shares. End-user markets in biomedical research continue to be challenging for Harvard, says the analyst, who is lowering estimates as a result.